Pharmacorp Rx Inc. PCRX

Acquisition of a PharmaChoice Canada-bannered pharmacy in Western Canada completed at a purchase price of $1,300,000, subject to customary post-closing adjustmentsThe acquisition increases PharmaCorp’s operating network to 17 pharmaciesPreviously announced purchase of the prescription files of an I.D.A.-bannered pharmacy in Western Canada completed at a purchase price of $475,000, subject to customary post-closing adjustmentsCanadian Imperial Bank of Commerce acquisition facility increased by $1

SASKATOON, Saskatchewan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- PharmaCorp Rx Inc. (TSXV: PCRX) (“PharmaCorp” or the “Corporation”) today announced changes to its Board of Directors, Board committee leadership and Corporate Secretary as the Corporation prepares for its 2026 Annual General and Special Meeting of Security Holders (the “2026 AGSM”). Effective August 31, 2026, Calvin Leroux will step down as a director of PharmaCorp and as Chair of the Corporation’s Corporate Governance and Compensation

Second quarter 2026 revenue up 75.8% compared to the second quarter of 2025Second quarter 2026 gross profit increased 78.2% compared to the second quarter of 2025Second quarter same-store sales were up 3.8%, and same-store prescription sales were up 5.2%, both compared to the second quarter of 2025 SASKATOON, Saskatchewan, Aug. 20, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a Canadian pharmacy services and consolidation platform, today reported i

Purchase price of approximately $2.47 millionAcquisition increases PharmaCorp's operating network to 16 pharmaciesNew definitive share purchase agreement executed for a PharmaChoice Canada-bannered pharmacy in Western Canada at a purchase price of approximately $1.3 millionNew definitive asset purchase agreement executed for the prescription files of an I.D.A.-bannered pharmacy in Western CanadaSaskatoon, Saskatchewan--(Newsfile Corp. - August 18, 2026) - PHARMACORP RX INC. (TSXV:...

Purchase price of approximately $8.1 millionAcquisition increases PharmaCorp's operating network to 15 pharmacies Previously announced second definitive share purchase agreement has received preliminary college approval and is anticipated to close on or about August 17, 2026Additional non-binding letter of intent executed for a proposed pharmacy acquisition in Western CanadaSaskatoon, Saskatchewan--(Newsfile Corp. - July 31, 2026) - PHARMACORP RX INC. (TSXV: PCRX) ("PharmaCorp" or the...

PharmaCorp Rx Inc. ("PharmaCorp" or the "Company") (TSXV: PCRX) is pleased to announce that it has closed its previously announced bought deal public offering co-led by Acumen Capital Finance Partners Limited and Canaccord Genuity Corp., and including Raymond James Ltd. (collectively, the "Underwriters") pursuant to which the Underwriters purchased, on a bought deal basis, 22,549,200 units (the "Units") in the capital of the Company at a price of C$0.51 per Unit (the "Offering Price") for aggreg

PHARMACORP RX INC. ("PharmaCorp" or the "Company") (TSXV: PCRX) is pleased to announce that it has entered into an agreement with a syndicate of underwriters (the "Underwriters") co-led by Acumen Capital Finance Partners Limited ("Acumen") and Canaccord Genuity Corp. pursuant to which the Underwriters have agreed to purchase, on a bought deal basis, 19,608,000 units (the "Units") in the capital of the Company at a price of C$0.51 per Unit (the "Offering Price") for aggregate gross proceeds to th

Purchase price of approximately $2.47 million Second of four previously announced letters of intent (LOIs) converted into a definitive agreementOn closing, expected to increase PharmaCorp's store count to 16 pharmacies, assuming completion of previously announced acquisitionsSaskatoon, Saskatchewan--(Newsfile Corp. - June 29, 2026) - PHARMACORP RX INC. (TSXV: PCRX) ("PharmaCorp" or the "Corporation"), a Canadian pharmacy acquisition and ownership platform for pharmacist-led community pharmacy...

First quarter 2026 revenue up 79.4% compared to the first quarter of 2025First quarter 2026 gross profit increased 71.9% compared to the first quarter of 2025First quarter same-store sales were up 7.3%, and same-store prescription sales were up 7.2%, both compared to the first quarter of 2025 SASKATOON, Saskatchewan, June 01, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a Canadian pharmacy services and consolidation platform, today reported its fin

The acquisition of eight pharmacies at an aggregate purchase price of approximately $24.2 millionThe acquisitions are expected to increase PharmaCorp’s store count from six to fourteen locations, reflecting the planned integration of the two Western Canada locations acquired on October 1, 2025. SASKATOON, Saskatchewan, April 30, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a Canadian pharmacy acquisition and ownership platform for pharmacist-led co

Fourth quarter 2025 revenue up 75% compared to the fourth quarter 2024Fourth quarter 2025 gross profit increased 78% compared to the fourth quarter 2025Fourth quarter same-store sales up 6% and same-store prescription sales up 3.8 %, supplementary financial measures, both compared to fourth quarter 2025 SASKATOON, Saskatchewan, April 29, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) a Canadian pharmacy acquisition and ownership platform for pharmaci

SASKATOON, Saskatchewan, April 13, 2026 (GLOBE NEWSWIRE) -- PHARMACORP RX INC. (“PharmaCorp” or the “Corporation”) (TSXV: PCRX) is pleased to announce it has entered into a public listing services agreement (the “Agreement”) with LodeRock Advisors Inc. (“LodeRock”) to provide the Corporation with investor relations services, with a primary focus on developing and executing a 12‑month investor relations strategy, advising senior management on investor‑related matters, and maintaining strong relat